Thromboembolic Risk in Juvenile Dermatomyositis Patients Treated With Intravenous Immunoglobulin.
Publication/Presentation Date
1-1-2025
Abstract
This single-institution retrospective cohort study evaluates the risk of thromboembolic events (TE) in patients with juvenile dermatomyositis (JDM) treated with intravenous immunoglobulin (IVIg). We found no difference in the occurrence of TE in JDM patients treated with IVIg as compared to those without IVIg exposure; both cohorts had no TEs. Patients in both JDM cohorts had matched levels of other clotting risk factors, such as periods of limited mobility and hormonal contraceptive use. This research supports the growing body of evidence in the adult DM population demonstrating no significantly increased risk of TE attributable to IVIg and suggests that the occurrence of TE in JDM is low.
Volume
42
Issue
3
First Page
577
Last Page
579
ISSN
1525-1470
Published In/Presented At
Gomes, L. L. A., Silva, G. S., Carol, H. A., Subhadarshani, S., Rutstein, B. H., & Shaw, K. S. (2025). Thromboembolic Risk in Juvenile Dermatomyositis Patients Treated With Intravenous Immunoglobulin. Pediatric dermatology, 42(3), 577–579. https://doi.org/10.1111/pde.15865
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
39789776
Department(s)
Administration and Leadership
Document Type
Article